You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Not enough Covid-19 vaccines for everybody till 2024 end: Adar Poonawalla

Poonawalla estimates that the world will need 15 billion doses of the vaccine if it is taken in two steps

Serum Institute of India | Coronavirus Vaccine | AstraZeneca

BS Web Team  |  New Delhi 

Adar Poonawalla, CEO, Serum Institute
Poonawalla said that the commitment of his firm exceeded that of the other firms.

Adar Poonawalla, CEO of the Serum Institute of India, has warned that it will take at least four years to make enough Covid-19 vaccines for the entire world, according to an interview in the Financial Times.

He added that the long wait was due to the fact that pharmaceutical companies were not ramping up their production levels quickly enough to vaccinate the global population in less time. “It’s going to take four to five years until everyone gets the vaccine on this planet," said Poonawalla.

According to FT, Poonawalla estimates the world will need 15 billion doses of vaccine if it is taken in two steps.

Serum Institute has partnered with five international pharmaceutical firms, including and Novavax, to develop a Covid-19 vaccine and has committed to produce 1 billion doses, of which it has pledged half to India.

The company may also partner with Russia’s Gamaleya Research Institute to manufacture the Sputnik vaccine. Poonawalla said that the commitment of his firm exceeded that of the other vaccine producers.

His comments come a day after Union Health Minister Dr said no date had been fixed yet and that the vaccine might be available in the first quarter of 2021. “It may be ready by the first quarter of next year,” the minister said in the first episode of his Sunday Samvaad — a social media interaction programme.

Serum Institute is the world’s largest vaccine manufacturer by volume, producing 1.5 bn doses of vaccines annually for use in more than 170 countries to protect against many infectious diseases, such as polio, measles and influenza.

As part of its agreement with AstraZeneca, the company will aim to produce vaccine doses that cost around $3 for 68 countries and under its agreement with Novavax, for 92 countries.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, September 14 2020. 23:22 IST